

Global Prostate Cancer Diagnostics Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G77CA2C6B1AFEN.html>

Date: April 2026

Pages: 116

Price: US\$ 4,480.00 (Single User License)

ID: G77CA2C6B1AFEN

Abstracts

The global Prostate Cancer Diagnostics market size is expected to reach \$ 28538 million by 2032, rising at a market growth of 7.6% CAGR during the forecast period (2026-2032).

Prostate Cancer Diagnostics refers to a comprehensive set of technologies and products used for the screening, detection, classification, and risk stratification of prostate cancer. It encompasses serum biomarker testing, imaging examinations, molecular diagnostics, biomarker analysis, and histopathological evaluation. Traditional approaches are based on prostate-specific antigen testing, combined with digital rectal examination and biopsy for confirmation. In recent years, multiparametric magnetic resonance imaging, liquid biopsy, gene expression profiling, and multi-parameter algorithmic models have been increasingly adopted, improving early detection and risk stratification accuracy. The core value of prostate cancer diagnostics lies in enabling early screening, reducing overtreatment, supporting personalized therapeutic decisions, and playing a pivotal role in the full-cycle management of oncology care within precision medicine frameworks. The average gross profit margin of this product is 35%.

Accelerating population aging and growing awareness of men's health provide a solid foundation for expanding prostate cancer screening demand. Healthcare systems are strengthening early cancer screening strategies, broadening coverage across target populations. The advancement of precision medicine has positioned genetic testing and molecular subtyping as major growth drivers. Upgrades in imaging technologies and the integration of artificial intelligence into diagnostic workflows have improved accuracy and efficiency. In addition, the expansion of commercial insurance and premium health check-up markets has enhanced the penetration of high-value diagnostic products. Overall, technological innovation and supportive policies are propelling the industry

toward high-quality development.

Prostate-specific antigen testing carries risks of false positives and overdiagnosis, potentially leading to unnecessary biopsies and treatments, thereby increasing healthcare burden and patient anxiety. Variations in screening guidelines across countries affect market expansion dynamics. The high cost of advanced molecular tests and imaging equipment limits penetration in primary healthcare settings. Uncertainties in reimbursement policies and cost-containment pressures may slow commercialization of innovative products. Furthermore, growing concerns over data privacy and genetic information security impose stricter compliance requirements on industry participants.

Downstream demand is concentrated in general hospitals, specialized oncology centers, independent clinical laboratories, and premium health screening institutions. Screening strategies are shifting from single-parameter testing toward multi-marker risk assessment and personalized management. Non-invasive or minimally invasive diagnostic approaches are increasingly favored by patients, expanding the application of liquid biopsy and gene expression testing. The convergence of imaging and molecular diagnostics supports multidisciplinary collaboration models. As chronic disease management concepts deepen, prostate cancer diagnostics are becoming integrated into long-term health management systems.

The upstream segment includes key materials such as antibodies, diagnostic reagents, enzymes, nucleic acid probes, diagnostic chips, and core imaging components. High-quality monoclonal antibodies and standardized calibrators directly influence test sensitivity and specificity. Molecular diagnostics rely on high-purity enzymes, primers, probes, and stable reagent systems. Imaging diagnostics depend on precision electronic components and advanced software algorithms. With the growing emphasis on domestic substitution and supply chain localization, upstream material self-sufficiency has become a critical competitive factor in the industry.

This report studies the global Prostate Cancer Diagnostics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Prostate Cancer Diagnostics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Prostate Cancer Diagnostics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Prostate Cancer Diagnostics total market, 2021-2032, (USD Million)

Global Prostate Cancer Diagnostics total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Prostate Cancer Diagnostics total market, key domestic companies, and share, (USD Million)

Global Prostate Cancer Diagnostics revenue by player, revenue and market share 2021-2026, (USD Million)

Global Prostate Cancer Diagnostics total market by Type, CAGR, 2021-2032, (USD Million)

Global Prostate Cancer Diagnostics total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Prostate Cancer Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Prostate Cancer Diagnostics market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Prostate Cancer Diagnostics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Prostate Cancer Diagnostics Market, Segmentation by Type:

Tumor Biomarker Tests

Imaging

Biopsy

Other

Global Prostate Cancer Diagnostics Market, Segmentation by Clinical Application:

Early Screening

Diagnostic Confirmation

Risk Stratification

Therapy Monitoring

Global Prostate Cancer Diagnostics Market, Segmentation by End Users:

Hospital & Clinic

Third-party Laboratory

Other

Global Prostate Cancer Diagnostics Market, Segmentation by Application:

Age Below 55

Age 55-75

Age Above 75

Companies Profiled:

OPKO

Genomic Health

Abbott

Beckman Coulter

Siemens Healthcare

bioMeriux

Roche

MDx Health

DiaSorin

Myriad Genetics

Ambry Genetics

Key Questions Answered

1. How big is the global Prostate Cancer Diagnostics market?
2. What is the demand of the global Prostate Cancer Diagnostics market?
3. What is the year over year growth of the global Prostate Cancer Diagnostics market?
4. What is the total value of the global Prostate Cancer Diagnostics market?
5. Who are the Major Players in the global Prostate Cancer Diagnostics market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Prostate Cancer Diagnostics Introduction
- 1.2 World Prostate Cancer Diagnostics Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Prostate Cancer Diagnostics Total Market by Region (by Headquarter Location)
 - 1.3.1 World Prostate Cancer Diagnostics Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.3 China Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.4 Europe Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.5 Japan Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
 - 1.3.8 India Based Company Prostate Cancer Diagnostics Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Prostate Cancer Diagnostics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.2 World Prostate Cancer Diagnostics Consumption Value by Region
 - 2.2.1 World Prostate Cancer Diagnostics Consumption Value by Region (2021-2026)
 - 2.2.2 World Prostate Cancer Diagnostics Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.4 China Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.5 Europe Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.6 Japan Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.7 South Korea Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.8 ASEAN Prostate Cancer Diagnostics Consumption Value (2021-2032)
- 2.9 India Prostate Cancer Diagnostics Consumption Value (2021-2032)

3 WORLD PROSTATE CANCER DIAGNOSTICS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Prostate Cancer Diagnostics Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Prostate Cancer Diagnostics Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Prostate Cancer Diagnostics in 2025
 - 3.2.3 Global Concentration Ratios (CR8) for Prostate Cancer Diagnostics in 2025
- 3.3 Prostate Cancer Diagnostics Company Evaluation Quadrant
- 3.4 Prostate Cancer Diagnostics Market: Overall Company Footprint Analysis
 - 3.4.1 Prostate Cancer Diagnostics Market: Region Footprint
 - 3.4.2 Prostate Cancer Diagnostics Market: Company Product Type Footprint
 - 3.4.3 Prostate Cancer Diagnostics Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Prostate Cancer Diagnostics Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Prostate Cancer Diagnostics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: Prostate Cancer Diagnostics Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: Prostate Cancer Diagnostics Consumption Value Comparison
 - 4.2.1 United States VS China: Prostate Cancer Diagnostics Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: Prostate Cancer Diagnostics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based Prostate Cancer Diagnostics Companies and Market Share, 2021-2026
 - 4.3.1 United States Based Prostate Cancer Diagnostics Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies Prostate Cancer Diagnostics Revenue,

(2021-2026)

4.4 China Based Companies Prostate Cancer Diagnostics Revenue and Market Share, 2021-2026

4.4.1 China Based Prostate Cancer Diagnostics Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Prostate Cancer Diagnostics Revenue, (2021-2026)

4.5 Rest of World Based Prostate Cancer Diagnostics Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Prostate Cancer Diagnostics Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Prostate Cancer Diagnostics Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Prostate Cancer Diagnostics Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Tumor Biomarker Tests

5.2.2 Imaging

5.2.3 Biopsy

5.2.4 Other

5.3 Market Segment by Type

5.3.1 World Prostate Cancer Diagnostics Market Size by Type (2021-2026)

5.3.2 World Prostate Cancer Diagnostics Market Size by Type (2027-2032)

5.3.3 World Prostate Cancer Diagnostics Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY CLINICAL APPLICATION

6.1 World Prostate Cancer Diagnostics Market Size Overview by Clinical Application: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Clinical Application

6.2.1 Early Screening

6.2.2 Diagnostic Confirmation

6.2.3 Risk Stratification

6.2.4 Therapy Monitoring

6.3 Market Segment by Clinical Application

6.3.1 World Prostate Cancer Diagnostics Market Size by Clinical Application

(2021-2026)

6.3.2 World Prostate Cancer Diagnostics Market Size by Clinical Application

(2027-2032)

6.3.3 World Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2027-2032)

7 MARKET ANALYSIS BY END USERS

7.1 World Prostate Cancer Diagnostics Market Size Overview by End Users: 2021 VS 2025 VS 2032

7.2 Segment Introduction by End Users

7.2.1 Hospital & Clinic

7.2.2 Third-party Laboratory

7.2.3 Other

7.3 Market Segment by End Users

7.3.1 World Prostate Cancer Diagnostics Market Size by End Users (2021-2026)

7.3.2 World Prostate Cancer Diagnostics Market Size by End Users (2027-2032)

7.3.3 World Prostate Cancer Diagnostics Market Size Market Share by End Users (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Prostate Cancer Diagnostics Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Age Below

8.2.2 Age 55-75

8.2.3 Age Above

8.3 Market Segment by Application

8.3.1 World Prostate Cancer Diagnostics Market Size by Application (2021-2026)

8.3.2 World Prostate Cancer Diagnostics Market Size by Application (2027-2032)

8.3.3 World Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 OPKO

9.1.1 OPKO Details

9.1.2 OPKO Major Business

- 9.1.3 OPKO Prostate Cancer Diagnostics Product and Services
- 9.1.4 OPKO Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
- 9.1.5 OPKO Recent Developments/Updates
- 9.1.6 OPKO Competitive Strengths & Weaknesses
- 9.2 Genomic Health
 - 9.2.1 Genomic Health Details
 - 9.2.2 Genomic Health Major Business
 - 9.2.3 Genomic Health Prostate Cancer Diagnostics Product and Services
 - 9.2.4 Genomic Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.2.5 Genomic Health Recent Developments/Updates
 - 9.2.6 Genomic Health Competitive Strengths & Weaknesses
- 9.3 Abbott
 - 9.3.1 Abbott Details
 - 9.3.2 Abbott Major Business
 - 9.3.3 Abbott Prostate Cancer Diagnostics Product and Services
 - 9.3.4 Abbott Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.3.5 Abbott Recent Developments/Updates
 - 9.3.6 Abbott Competitive Strengths & Weaknesses
- 9.4 Beckman Coulter
 - 9.4.1 Beckman Coulter Details
 - 9.4.2 Beckman Coulter Major Business
 - 9.4.3 Beckman Coulter Prostate Cancer Diagnostics Product and Services
 - 9.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.4.5 Beckman Coulter Recent Developments/Updates
 - 9.4.6 Beckman Coulter Competitive Strengths & Weaknesses
- 9.5 Siemens Healthcare
 - 9.5.1 Siemens Healthcare Details
 - 9.5.2 Siemens Healthcare Major Business
 - 9.5.3 Siemens Healthcare Prostate Cancer Diagnostics Product and Services
 - 9.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.5.5 Siemens Healthcare Recent Developments/Updates
 - 9.5.6 Siemens Healthcare Competitive Strengths & Weaknesses
- 9.6 bioMeriux
 - 9.6.1 bioMeriux Details

- 9.6.2 bioMeriux Major Business
- 9.6.3 bioMeriux Prostate Cancer Diagnostics Product and Services
- 9.6.4 bioMeriux Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
- 9.6.5 bioMeriux Recent Developments/Updates
- 9.6.6 bioMeriux Competitive Strengths & Weaknesses
- 9.7 Roche
 - 9.7.1 Roche Details
 - 9.7.2 Roche Major Business
 - 9.7.3 Roche Prostate Cancer Diagnostics Product and Services
 - 9.7.4 Roche Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.7.5 Roche Recent Developments/Updates
 - 9.7.6 Roche Competitive Strengths & Weaknesses
- 9.8 MDx Health
 - 9.8.1 MDx Health Details
 - 9.8.2 MDx Health Major Business
 - 9.8.3 MDx Health Prostate Cancer Diagnostics Product and Services
 - 9.8.4 MDx Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.8.5 MDx Health Recent Developments/Updates
 - 9.8.6 MDx Health Competitive Strengths & Weaknesses
- 9.9 DiaSorin
 - 9.9.1 DiaSorin Details
 - 9.9.2 DiaSorin Major Business
 - 9.9.3 DiaSorin Prostate Cancer Diagnostics Product and Services
 - 9.9.4 DiaSorin Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.9.5 DiaSorin Recent Developments/Updates
 - 9.9.6 DiaSorin Competitive Strengths & Weaknesses
- 9.10 Myriad Genetics
 - 9.10.1 Myriad Genetics Details
 - 9.10.2 Myriad Genetics Major Business
 - 9.10.3 Myriad Genetics Prostate Cancer Diagnostics Product and Services
 - 9.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
 - 9.10.5 Myriad Genetics Recent Developments/Updates
 - 9.10.6 Myriad Genetics Competitive Strengths & Weaknesses
- 9.11 Ambry Genetics

- 9.11.1 Ambry Genetics Details
- 9.11.2 Ambry Genetics Major Business
- 9.11.3 Ambry Genetics Prostate Cancer Diagnostics Product and Services
- 9.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026)
- 9.11.5 Ambry Genetics Recent Developments/Updates
- 9.11.6 Ambry Genetics Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

- 10.1 Prostate Cancer Diagnostics Industry Chain
- 10.2 Prostate Cancer Diagnostics Upstream Analysis
- 10.3 Prostate Cancer Diagnostics Midstream Analysis
- 10.4 Prostate Cancer Diagnostics Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

- 12.1 Methodology
- 12.2 Research Process and Data Source
- 12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Prostate Cancer Diagnostics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Prostate Cancer Diagnostics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Prostate Cancer Diagnostics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Prostate Cancer Diagnostics Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Prostate Cancer Diagnostics Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Prostate Cancer Diagnostics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Prostate Cancer Diagnostics Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Prostate Cancer Diagnostics Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Prostate Cancer Diagnostics Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Prostate Cancer Diagnostics Players in 2025

Table 12. World Prostate Cancer Diagnostics Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Prostate Cancer Diagnostics Company Evaluation Quadrant

Table 14. Head Office of Key Prostate Cancer Diagnostics Players

Table 15. Prostate Cancer Diagnostics Market: Company Product Type Footprint

Table 16. Prostate Cancer Diagnostics Market: Company Product Application Footprint

Table 17. Prostate Cancer Diagnostics Mergers & Acquisitions Activity

Table 18. United States VS China Prostate Cancer Diagnostics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Prostate Cancer Diagnostics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Prostate Cancer Diagnostics Companies, Headquarters (States, Country)

Table 21. United States Based Companies Prostate Cancer Diagnostics Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Prostate Cancer Diagnostics Revenue Market Share (2021-2026)

Table 23. China Based Prostate Cancer Diagnostics Companies, Headquarters (Province, Country)

Table 24. China Based Companies Prostate Cancer Diagnostics Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Prostate Cancer Diagnostics Revenue Market Share (2021-2026)

Table 26. Rest of World Based Prostate Cancer Diagnostics Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Prostate Cancer Diagnostics Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Prostate Cancer Diagnostics Revenue Market Share (2021-2026)

Table 29. World Prostate Cancer Diagnostics Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Prostate Cancer Diagnostics Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Prostate Cancer Diagnostics Market Size by Type (2027-2032) & (USD Million)

Table 32. World Prostate Cancer Diagnostics Market Size by Clinical Application, (USD Million), 2021 & 2025 & 2032

Table 33. World Prostate Cancer Diagnostics Market Size Value by Clinical Application (2021-2026) & (USD Million)

Table 34. World Prostate Cancer Diagnostics Market Size by Clinical Application (2027-2032) & (USD Million)

Table 35. World Prostate Cancer Diagnostics Market Size by End Users, (USD Million), 2021 & 2025 & 2032

Table 36. World Prostate Cancer Diagnostics Market Size Value by End Users (2021-2026) & (USD Million)

Table 37. World Prostate Cancer Diagnostics Market Size by End Users (2027-2032) & (USD Million)

Table 38. World Prostate Cancer Diagnostics Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World Prostate Cancer Diagnostics Market Size by Application (2021-2026) & (USD Million)

Table 40. World Prostate Cancer Diagnostics Market Size by Application (2027-2032) & (USD Million)

Table 41. OPKO Basic Information, Manufacturing Base and Competitors

- Table 42. OPKO Major Business
- Table 43. OPKO Prostate Cancer Diagnostics Product and Services
- Table 44. OPKO Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 45. OPKO Recent Developments/Updates
- Table 46. OPKO Competitive Strengths & Weaknesses
- Table 47. Genomic Health Basic Information, Manufacturing Base and Competitors
- Table 48. Genomic Health Major Business
- Table 49. Genomic Health Prostate Cancer Diagnostics Product and Services
- Table 50. Genomic Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 51. Genomic Health Recent Developments/Updates
- Table 52. Genomic Health Competitive Strengths & Weaknesses
- Table 53. Abbott Basic Information, Manufacturing Base and Competitors
- Table 54. Abbott Major Business
- Table 55. Abbott Prostate Cancer Diagnostics Product and Services
- Table 56. Abbott Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 57. Abbott Recent Developments/Updates
- Table 58. Abbott Competitive Strengths & Weaknesses
- Table 59. Beckman Coulter Basic Information, Manufacturing Base and Competitors
- Table 60. Beckman Coulter Major Business
- Table 61. Beckman Coulter Prostate Cancer Diagnostics Product and Services
- Table 62. Beckman Coulter Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 63. Beckman Coulter Recent Developments/Updates
- Table 64. Beckman Coulter Competitive Strengths & Weaknesses
- Table 65. Siemens Healthcare Basic Information, Manufacturing Base and Competitors
- Table 66. Siemens Healthcare Major Business
- Table 67. Siemens Healthcare Prostate Cancer Diagnostics Product and Services
- Table 68. Siemens Healthcare Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 69. Siemens Healthcare Recent Developments/Updates
- Table 70. Siemens Healthcare Competitive Strengths & Weaknesses
- Table 71. bioMeriux Basic Information, Manufacturing Base and Competitors
- Table 72. bioMeriux Major Business
- Table 73. bioMeriux Prostate Cancer Diagnostics Product and Services
- Table 74. bioMeriux Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 75. bioMeriux Recent Developments/Updates
- Table 76. bioMeriux Competitive Strengths & Weaknesses
- Table 77. Roche Basic Information, Manufacturing Base and Competitors
- Table 78. Roche Major Business
- Table 79. Roche Prostate Cancer Diagnostics Product and Services
- Table 80. Roche Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 81. Roche Recent Developments/Updates
- Table 82. Roche Competitive Strengths & Weaknesses
- Table 83. MDx Health Basic Information, Manufacturing Base and Competitors
- Table 84. MDx Health Major Business
- Table 85. MDx Health Prostate Cancer Diagnostics Product and Services
- Table 86. MDx Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 87. MDx Health Recent Developments/Updates
- Table 88. MDx Health Competitive Strengths & Weaknesses
- Table 89. DiaSorin Basic Information, Manufacturing Base and Competitors
- Table 90. DiaSorin Major Business
- Table 91. DiaSorin Prostate Cancer Diagnostics Product and Services
- Table 92. DiaSorin Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 93. DiaSorin Recent Developments/Updates
- Table 94. DiaSorin Competitive Strengths & Weaknesses
- Table 95. Myriad Genetics Basic Information, Manufacturing Base and Competitors
- Table 96. Myriad Genetics Major Business
- Table 97. Myriad Genetics Prostate Cancer Diagnostics Product and Services
- Table 98. Myriad Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 99. Myriad Genetics Recent Developments/Updates
- Table 100. Myriad Genetics Competitive Strengths & Weaknesses
- Table 101. Ambry Genetics Basic Information, Manufacturing Base and Competitors
- Table 102. Ambry Genetics Major Business
- Table 103. Ambry Genetics Prostate Cancer Diagnostics Product and Services
- Table 104. Ambry Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 105. Ambry Genetics Recent Developments/Updates
- Table 106. Ambry Genetics Competitive Strengths & Weaknesses
- Table 107. Global Key Players of Prostate Cancer Diagnostics Upstream (Raw Materials)

Table 108. Global Prostate Cancer Diagnostics Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Prostate Cancer Diagnostics Picture

Figure 2. World Prostate Cancer Diagnostics Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Prostate Cancer Diagnostics Total Revenue (2021-2032) & (USD Million)

Figure 4. World Prostate Cancer Diagnostics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World Prostate Cancer Diagnostics Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company Prostate Cancer Diagnostics Revenue (2021-2032) & (USD Million)

Figure 13. Prostate Cancer Diagnostics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 16. World Prostate Cancer Diagnostics Consumption Value Market Share by Region (2021-2032)

Figure 17. United States Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 18. China Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 23. India Prostate Cancer Diagnostics Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Prostate Cancer Diagnostics by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Prostate Cancer Diagnostics Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Prostate Cancer Diagnostics Markets in 2025

Figure 27. United States VS China: Prostate Cancer Diagnostics Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Prostate Cancer Diagnostics Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Prostate Cancer Diagnostics Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Prostate Cancer Diagnostics Market Size Market Share by Type in 2025

Figure 31. Tumor Biomarker Tests

Figure 32. Imaging

Figure 33. Biopsy

Figure 34. Other

Figure 35. World Prostate Cancer Diagnostics Market Size Market Share by Type (2021-2032)

Figure 36. World Prostate Cancer Diagnostics Market Size by Clinical Application, (USD Million), 2021 & 2025 & 2032

Figure 37. World Prostate Cancer Diagnostics Market Size Market Share by Clinical Application in 2025

Figure 38. Early Screening

Figure 39. Diagnostic Confirmation

Figure 40. Risk Stratification

Figure 41. Therapy Monitoring

Figure 42. World Prostate Cancer Diagnostics Market Size Market Share by Clinical Application (2021-2032)

Figure 43. World Prostate Cancer Diagnostics Market Size by End Users, (USD Million),

2021 & 2025 & 2032

Figure 44. World Prostate Cancer Diagnostics Market Size Market Share by End Users in 2025

Figure 45. Hospital & Clinic

Figure 46. Third-party Laboratory

Figure 47. Other

Figure 48. World Prostate Cancer Diagnostics Market Size Market Share by End Users (2021-2032)

Figure 49. World Prostate Cancer Diagnostics Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 50. World Prostate Cancer Diagnostics Market Size Market Share by Application in 2025

Figure 51. Age Below 55

Figure 52. Age 55-75

Figure 53. Age Above 75

Figure 54. World Prostate Cancer Diagnostics Market Size Market Share by Application (2021-2032)

Figure 55. Prostate Cancer Diagnostics Industrial Chain

Figure 56. Methodology

Figure 57. Research Process and Data Source

I would like to order

Product name: Global Prostate Cancer Diagnostics Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G77CA2C6B1AFEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G77CA2C6B1AFEN.html>